e on WaferGen's core competencies – engineering and validation of a variety of chemistries to provide an open format for cost-effective gene expression and genotyping analysis, as well as target enrichment for NGS. Our customers will be able to load their custom content on our chips and conduct experiments of their own design by leveraging the unique features of our platform," added Mr. Trifunovich.
In addition to flexibility and cost effectiveness, WaferGen believes that its chip with the 100nL per well volume captures the "sweet spot" for balancing the trade-off between miniaturization and sensitivity and dynamic range. These three key competitive advantages will position the Company to become a leading provider of high-end qPCR solutions for the rapidly growing market driven by new genomic applications dominated by next generation sequencing. As the discovery of new targets grows rapidly, WaferGen's platform will be ideally suited for target validation and development of new diagnostic markers.
About WaferGen and the SmartChip Real-Time PCR System
WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.
For additional information, please see http://www.wafergen.com
Forward Looking Statements
This press release contains certain "forward-looking statements." Such statements include statements relating to the expected benefits to the Company of its new open format qPCR platform and strategic realignment, the expected
Page: 1 2 3 Related biology technology :1
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 20122
. WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference3
. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy4
. WaferGen Announces Delay in Reporting of Second Quarter 2011 Results5
. WaferGen Announces $30 Million Financing6
. WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing7
. WaferGen Announces General Availability of Quick-Turnaround SmartChip Custom Panels8
. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications9
. WaferGen Corporate Presentation to be Webcast at Rodman and Renshaws 12th Annual Healthcare Conference10
. WaferGen to Launch Human MicroRNA Panel for Gene-Expression Profiling of 885 MicroRNA for Its Service Using the SmartChip(TM) Real-Time PCR System11
. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System